Department of Neurology, Developmental Neurobiology, University Hospital Würzburg, Würzburg, Germany.
J Peripher Nerv Syst. 2023 Sep;28(3):341-350. doi: 10.1111/jns.12561. Epub 2023 May 29.
The complex cellular and molecular interactions between Schwann cells (SCs) and macrophages during Wallerian degeneration are a prerequisite to allow rapid uptake and degradation of myelin debris and axonal regeneration after peripheral nerve injury. In contrast, in non-injured nerves of Charcot-Marie-Tooth 1 neuropathies, aberrant macrophage activation by SCs carrying myelin gene defects is a disease amplifier that drives nerve damage and subsequent functional decline. Consequently, targeting nerve macrophages might be a translatable treatment strategy to mitigate disease outcome in CMT1 patients. Indeed, in previous approaches, macrophage targeting alleviated the axonopathy and promoted sprouting of damaged fibers. Surprisingly, this was still accompanied by robust myelinopathy in a model for CMT1X, suggesting additional cellular mechanisms of myelin degradation in mutant peripheral nerves. We here investigated the possibility of an increased SC-related myelin autophagy upon macrophage targeting in Cx32def mice.
Combining ex vivo and in vivo approaches, macrophages were targeted by PLX5622 treatment. SC autophagy was investigated by immunohistochemical and electron microscopical techniques.
We demonstrate a robust upregulation of markers for SC autophagy after injury and in genetically-mediated neuropathy when nerve macrophages are pharmacologically depleted. Corroborating these findings, we provide ultrastructural evidence for increased SC myelin autophagy upon treatment in vivo.
These findings reveal a novel communication and interaction between SCs and macrophages. This identification of alternative pathways of myelin degradation may have important implications for a better understanding of therapeutic mechanisms of pharmacological macrophage targeting in diseased peripheral nerves.
施万细胞(SCs)与巨噬细胞之间复杂的细胞和分子相互作用是周围神经损伤后允许髓磷脂碎片快速摄取和降解以及轴突再生的前提。相比之下,在遗传性运动感觉神经病 1 型(Charcot-Marie-Tooth 1,CMT1)患者的非损伤神经中,携带髓磷脂基因缺陷的SCs 导致巨噬细胞异常激活,是驱动神经损伤和随后功能下降的疾病放大器。因此,针对神经巨噬细胞可能是一种可转化的治疗策略,可减轻 CMT1 患者的疾病结局。事实上,在之前的研究中,巨噬细胞靶向治疗减轻了轴突变性并促进了受损纤维的发芽。令人惊讶的是,在 CMT1X 的模型中,这仍然伴随着强烈的脱髓鞘,这表明突变周围神经中存在额外的髓磷脂降解细胞机制。我们在此研究了在 Cx32def 小鼠中靶向巨噬细胞后 Schwann 细胞相关髓磷脂自噬增加的可能性。
结合离体和体内方法,用 PLX5622 处理来靶向巨噬细胞。通过免疫组织化学和电子显微镜技术研究 Schwann 细胞自噬。
我们证明,在损伤后和遗传介导的神经病中,当神经巨噬细胞被药物耗尽时,SC 自噬的标志物会显著上调。这些发现得到了有力的支持,我们提供了体内治疗后 SC 髓磷脂自噬增加的超微结构证据。
这些发现揭示了 Schwann 细胞和巨噬细胞之间新的通讯和相互作用。这种对髓磷脂降解替代途径的识别可能对更好地理解药物靶向巨噬细胞在病变周围神经中的治疗机制具有重要意义。